On May 5, Kato Shengxin, Japan’s Prime Minister for Health and Labor, said that it was expected to approve Remdesivir as early as May 7 to treat new Crown pneumonia. According to a report by Japan’s Kyodo news agency on the 6th, Kato Shengxin revealed in a program on BS Fuji TV on the 5th, on the 7th, it was planned to discuss the approval of redsiwei’s pharmaceutical at a review meeting composed of experts. He also stressed that if it was agreed, “Redsiwei” will be approved as soon as possible for the treatment of new Crown pneumonia.
According to the report, Gilead Sciences, an American pharmaceutical company, applied to houlao province in May 4 for approval of the use of radsiwei in Japan. The thick Labor province has adopted a “special approval” system for this.
Kato Shengxin said that coordination is still needed on the amount of medicine Gilead supplies to Japan. He said that efforts will be made to obtain the necessary dosage so that critically ill patients can use it as soon as possible.
According to previous media reports, Red West Wei was considered to be the most promising drug against the new Crown virus, developed by Gilead Science, headquartered in California, USA. Redseway has shown some hope in treating SARS and Middle East Respiratory Syndrome (MERS), both of which are caused by a coronavirus.
On May 1, the U. S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the new Crown pneumonia treatment for the antiviral drug rethewei, which is still under study, it is used to treat severe patients with suspected or confirmed new Crown pneumonia, including adults and children.
On May 4, the World Health Organization (WHO) said it would discuss with the US government and Gilead Science how the treatment of new Crown pneumonia can be more widely available.
According to the Japan Broadcasting Association (NHK), as of 7: 00 P.M. local time on May 5, the cumulative number of confirmed cases of Japan’s new crown pneumonia reached 16080 and the death toll was 566.